

# Effects of vitamin D3, omega-3s, and a simple strength training exercise program on bone health: the DO-HEALTH randomized controlled trial

Melanie Kistler-Fischbacher<sup>1,2</sup>, Gabriele Armbrecht<sup>3</sup>, Stephanie Gängler<sup>1,2</sup>, Robert Theiler<sup>2</sup>, René Rizzoli<sup>4</sup>, Bess Dawson-Hughes<sup>5</sup>, John A. Kanis<sup>6</sup>, Lorenz C. Hofbauer<sup>7</sup>, Ralph C. Schimmer<sup>1</sup>, Bruno Vellas<sup>8,9</sup>, José A.P. Da Silva<sup>10,11</sup>, Orav E. John<sup>12</sup>, Reto W. Kressig<sup>13</sup>, Egli Andreas<sup>1,2</sup>, Wei Lang<sup>1,2</sup>, Guido A. Wanner<sup>14,†</sup>, Heike A. Bischoff-Ferrari<sup>1,2,15,\*</sup>, DO-HEALTH Research Group

<sup>1</sup>Department of Geriatric Medicine and Aging Research, University of Zurich, Zurich 8037, Switzerland

<sup>2</sup>Centre on Aging and Mobility, University of Zurich, Zurich 8037, Switzerland

<sup>3</sup>Department of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin 12203, Germany

<sup>4</sup>Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva 1211, Switzerland

<sup>5</sup>Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA 02111, United States

<sup>6</sup>Center for Metabolic Diseases, University of Sheffield Medical School, Sheffield S10 2TN, England

<sup>7</sup>Centre for Healthy Aging, Department of Medicine III, TU Dresden Medical Centre, Dresden 01307, Germany

<sup>8</sup>IHU HealthAge, Gérontopôle de Toulouse, Institut du Vieillissement, Centre Hospitalo-Universitaire de Toulouse, Toulouse 31059, France

<sup>9</sup>UMR INSERM 1027, University of Toulouse III, Toulouse 31062, France

<sup>10</sup>Centro Hospitalar e Universitário de Coimbra, Coimbra 3004-561, Portugal

<sup>11</sup>Coimbra Institute for Clinical and Biomedical Research (iCIBR), Faculty of Medicine, University of Coimbra, Coimbra 3004-504, Portugal

<sup>12</sup>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02120, United States

<sup>13</sup>University Department of Geriatric Medicine FELIX PLATTER, Basel 4055, Switzerland

<sup>14</sup>Spine Clinic and Traumatology, Private Hospital Bethanien, Zurich 8044, Switzerland

<sup>15</sup>IHU HealthAge, University Hospital Toulouse and University III Paul Sabatier Toulouse, Toulouse 31059, France

\*Corresponding author: Heike A. Bischoff-Ferrari, Department of Geriatrics and Aging Research, University of Zurich, Centre on Aging and Mobility, Tîechestrasse 99, 8037 Zürich, Switzerland (Heikea.bischoff-ferrari@uzh.ch).

†GAW and HAB-F share last authorship.

## Abstract

Evidence on the effects of Vitamin D, omega-3s, and exercise on areal bone mineral density (aBMD) in healthy older adults is limited. We examined whether vitamin D3, omega-3s, or a simple home-based exercise program (SHEP), alone or in combination, over 3 years, improve lumbar spine (LS), femoral neck (FN), or total hip (TH) aBMD assessed by DXA. Areal BMD was a secondary outcome in DO-HEALTH, a 3-year, multicenter, double-blind, randomized 2 × 2 × 2 factorial design trial in generally healthy older adults age ≥ 70 years. The study interventions were vitamin D3 (2000IU/d), omega-3s (1 g/d), and SHEP (3 × 30 min/wk), applied alone or in combination in eight treatment arms. Mixed effects models were used, adjusting for age, sex, BMI, prior fall, study site, and baseline level of the outcome. Main effects were assessed in the absence of an interaction between the interventions. Subgroup analyses by age, sex, physical activity level, dietary calcium intake, serum 25(OH)D levels, and fracture history were conducted. DXA scans were available for 1493 participants (mean age 75 years; 80.4% were physically active, 44% had 25(OH)D levels <20 ng/mL). At the LS and FN sites, none of the treatments showed a benefit. At the TH, vitamin D versus no vitamin D treatment showed a significant benefit across 3 years (difference in adjusted means [AM]: 0.0035 [95% CI, 0.0011, 0.0059] g/cm). Furthermore, there was a benefit for vitamin D versus no vitamin D treatment on LS aBMD in the male subgroup (interaction  $P = .003$ ;  $\Delta$ AM: 0.0070 [95% CI, 0.0007, 0.0132] g/cm). Omega-3s and SHEP had no benefit on aBMD in healthy, active, and largely vitamin D replete older adults. Our study suggests a small benefit of 2000 IU vitamin D daily on TH aBMD overall and LS aBMD among men; however, effect sizes were very modest and the clinical impact of these findings is unclear.

**Keywords:** aging, DXA, exercise, nutrition, osteoporosis

## Lay Summary

Vitamin D, omega-3 fatty acids (omega-3s), and strength training are simple but promising strategies to improve bone health; however, their effect in healthy older adults over a period of 3 years was unclear. In this study, we examined whether daily vitamin D supplementation (2000 IU/d), daily omega-3s supplementation (1 g/d), or a simple strength training program performed 3 times per week, either applied alone (eg, only vitamin D supplements) or in combination (eg, vitamin D and omega-3s supplements) could improve bone density at the spine, hip, or femoral neck. We included 1493 healthy older adults from Switzerland, Germany, France, and Portugal who were at least 70 years of age and who had not experienced any major health events in the 5 years before study start. Taking omega-3s supplements showed no benefit for bone density. Similarly, the simple strength exercise program showed no benefit. In contrast, participants receiving daily vitamin D supplements experienced a benefit at the hip. However, it should be noted that the effect across 3 years was very small.

Received: December 9, 2023. Revised: March 13, 2024. Accepted: March 23, 2024

© The Author(s) 2024. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

## Introduction

Osteoporosis is a progressive age-related condition characterized by loss of bone mass and deterioration of tissue microarchitecture,<sup>1,2</sup> resulting in an increased risk of fractures and associated personal, societal, and economic burden.<sup>2,3</sup> In 2019, ~4.3 million new osteoporotic fractures occurred in Europe, which is equivalent to eight new fractures every minute.<sup>2</sup> Osteoporotic fractures are associated with significant disability such as mobility impairment, chronic pain, loss of independence, and premature mortality.<sup>3–5</sup>

The primary goal of osteoporosis therapy is the prevention of fractures and should be aimed at modifiable risk factors, such as improving indices of bone strength. DXA-derived areal bone mineral density (aBMD) is the gold standard to measure changes in bone mass in clinical practice.<sup>6</sup> Areal BMD is a useful measure to monitor treatment response and assess fracture risk,<sup>7,8</sup> accounting for 60–70% of bone strength.<sup>9</sup> Quantification of other indices of bone strength, such as trabecular architecture estimated by trabecular bone score (TBS), can provide additional important information about mechanical resistance to fracture beyond aBMD.<sup>8,9</sup>

Supplementation with vitamin D or omega-3 fatty acids (omega-3s), and exercise have been suggested as public health strategies to increase bone health and consequently reduce fracture risk. Vitamin D exerts its effects on bone through the vitamin D receptor, which is expressed in osteoblasts,<sup>10</sup> and through intestinal calcium absorption.<sup>11</sup> The evidence on the effects of Vitamin D supplements in primary osteoporosis prevention is controversial.<sup>12,13,14,15</sup> Furthermore, inconsistent findings have been attributed to variation in dosing regimens (eg, daily vs. bolus dosing,<sup>16</sup> high vs. standard dose), co-administration of calcium supplements,<sup>17,18</sup> and limitations in trial designs (eg, short follow-up, small sample size).<sup>14</sup> The DO-HEALTH trial was specifically designed as a primary prevention trial<sup>19</sup> to contribute evidence on the effect of vitamin D on bone in generally healthy and active older adults, unselected for risk of vitamin D deficiency or osteoporosis.

Mechanistically, omega-3s may affect bone health by decreasing the levels of pro-inflammatory cytokines involved in the regulation of bone turnover and through up-regulation of vitamin-D-dependent intestinal calcium absorption.<sup>20</sup> Data from observational studies suggest an association between higher omega-3s intake and maintenance of femoral neck aBMD<sup>21</sup> and 45% reduced hip fracture risk,<sup>20</sup> compared with low intake. However, data from clinical trials on the effect of omega-3s on aBMD<sup>22,23</sup> are limited.

Exercise regulates bone remodeling through mechanotransduction, a process during which osteocytes sense and transform mechanical signals into intercellular signals which regulate bone turnover.<sup>24</sup> In addition, exercise can exert beneficial effects on bone through indirect pathways, for example through cytokines (eg, anti-inflammatory) or myokines.<sup>24</sup> The benefits of exercise on spine and proximal femur aBMD have been well documented, particularly for strength and resistance training interventions.<sup>25,26</sup>

Given the distinct mechanistic pathways and relevance of vitamin D, omega-3s, and exercise for bone health, we hypothesized that the combination of these interventions may exhibit greater benefits than either alone. However, this hypothesis could not be confirmed for the primary outcome non-vertebral fracture risk in DO-HEALTH, where none of the interventions had a benefit.<sup>27</sup> Of note, the fracture rate in DO-HEALTH was lower than expected. The effects of vitamin D

and omega-3s supplementation on fracture risk (any fracture, non-vertebral fractures, hip fractures) was also examined in the US VITAL trial, which, in line with DO-HEALTH, found no benefit for vitamin D and omega-3s (same doses as in DO-HEALTH) in 25 871 generally healthy adults age 50 years and older followed for a median of 5.3 years.<sup>28,29</sup>

In this analysis, we examine the individual and combined effects of vitamin D, omega-3s, and a simple home strength exercise program on aBMD, a predefined secondary outcome in DO-HEALTH, assessed in 1493 of 1503 DO-HEALTH participants recruited at four of seven recruitment sites. Furthermore, we explored treatment effects on TBS.

## Materials and methods

### Study design

DO-HEALTH was a double-blind, randomized controlled, 2 × 2 × 2 factorial design trial, designed to investigate six primary outcomes of healthy aging (diastolic and systolic blood pressure, Short Physical Performance Battery score, Montreal Cognitive Assessment Score, incidence of non-vertebral fractures and infections over 3 years). It included 2157 generally healthy older adults from seven study centers in five European countries.<sup>27</sup> DXA-derived aBMD at the lumbar spine (LS), femoral neck (FN), and total hip (TH) were predefined secondary outcomes in DO-HEALTH and measured in participants from four study centers, which were equipped with DXA scanners (Zurich, Switzerland; Berlin, Germany; Toulouse, France; Coimbra, Portugal). TBS was included as an additional analysis, which was not predefined. The detailed study protocol and statistical analysis plan have been published.<sup>19</sup>

The trial protocol was approved by regulatory agencies of all countries<sup>19</sup> and was registered in the International Trials Registry ([clinicaltrials.gov](https://clinicaltrials.gov), registration ID: NCT01745263) and the European Union Clinical Trials Register (Registration ID: 2012-001249-41). Approval for TBS analyses was obtained after completion of the trial from the ethics committee in Zurich (2023-01084).

### Study participants

Participants had to be ≥70 years of age, sufficiently mobile to come to the study center, living in the community, and score at least 24 points on the Mini Mental State Examination to be eligible for the trial. Exclusion criteria relevant to bone health and fracture risk included major health events in the 5 years prior to enrolment (eg, cancer, myocardial infarction, stroke), use of active vitamin D metabolites, parathyroid hormone (PTH) treatment (eg, teriparatide) or calcitonin, osteodystrophia deformans (Paget's disease), hypo- or hyperparathyroidism, and epilepsy or use of anti-convulsive drugs. Furthermore, participants had to be willing to limit calcium supplementation to a maximum dose of 500 mg/d, limit vitamin D supplementation to 800 IU/d, and forgo omega-3s supplementation for the duration of the 3-year trial. Participants with acute fractures within the past 6 weeks were only temporarily excluded and eligible after fracture healing. The full list of eligibility criteria has been published elsewhere.<sup>19</sup>

### Randomization and blinding

Participants were allocated to one of the eight treatment groups using computer-based (DO-HEALTH randomization software) stratified block (block size of 16 individuals)

randomization. Stratification was based on age (70–84 years,  $\geq 85$  years), sex, study center, and history of falling in the 12 months prior to enrolment (yes/no). Treatment allocation was concealed to investigators and participants. Qualified and trained study staff performed all assessments and examinations, according to standard operation procedures. All study staff, data analysts, and participants were blinded to group allocation, except for a physiotherapist who provided the instructions for the home exercise programs but was otherwise not involved in the trial.

## Interventions

Vitamin D capsules contained 1000 IU of vitamin D3 (cholecalciferol), stabilized with dl- $\alpha$ -tocopherol (vitamin E, 2.5 permille). Placebo capsules contained high oleic sunflower oil and were identical to vitamin D3 capsules in appearance. Participants were instructed to take two capsules per day, for a total dose of 2000 IU vitamin or placebo.

Omega-3s capsules contained 500 mg of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a ratio of 1:2. Placebo capsules contained high oleic sunflower oil and were identical with vitamin D3 capsules in appearance. Participants were instructed to take two capsules per day, for a total dose of 1000 mg of EPA and DHA, or placebo.

The simple home exercise program (SHEP) was a strength-training program which consisted of the following five exercises: sit-to-stand, one leg stance, pull back against elastic resistance, external shoulder rotation against elastic resistance, and stepping up and down one step on stairs. For each exercise, 3 sets of 10 repetitions were performed, except for single leg stance, where 10 sets of 10 s were performed for each leg. The control exercise program consisted of five mobility exercises targeting hip, knee, ankle, trunk, chest, and shoulder mobility. All participants were instructed to perform the exercises three times per week.

Adherence to the vitamin D and omega-3s interventions was assessed by participant self-report at each 3-monthly contact (phone calls and clinical visits), by measuring 25(OH)D and polyunsaturated fatty acid blood levels and through capsule counts of used, partially used and full bottles of study capsules which were returned by the participants at each visit. Exercise adherence was assessed by participant self-report at each 3-monthly contact (phone calls and clinical visits). All participants were given a study diary to record their adherence to the study interventions and support reporting of adherence to the study staff at in-person and phone visits. The information in the diary was not used as a direct source of information for adherence.

## Outcomes

Spine and proximal femur scans were acquired using dual-energy X-ray absorptiometry (DXA; Lunar iDXA, GE Healthcare machines were used at each of the four study sites) at each clinical visit (BL, 12, 24, and 36 months) and analyzed using enCORE software (Version 13.60.033). Predefined outcomes included in the DO-HEALTH study protocol included aBMD of the LS, FN, and TH. At baseline, both proximal femora were scanned, but only the side with the lower TH aBMD was measured at follow-up visits. If the side with lower aBMD at baseline became unsuitable for scanning, for example due to a fracture or endoprosthesis, the other side was used. For LS, L1-4 region was used and all evaluable vertebrae were included. If any of the vertebrae was affected by structure

change or artifact, three or otherwise two vertebrae were included for analysis. If only one evaluable vertebra remained, the participant was excluded from data analysis. Criteria for exclusion of vertebrae included degenerative changes, fractures, artifacts (eg, aortic calcification), or difference in T-score to adjacent vertebra of  $\pm 1$  SD.

TBS was measured as an additional, not predefined outcome, due its relevance to bone architecture and fracture risk. The integrated TBS software (TBS iNsight software v2.1; Medimaps, Geneva, Switzerland) was used for analysis. TBS analysis is based on standard spine DXA scans and quantifies variation in grey-level texture from 1 pixel to adjacent pixels. It provides an index of trabecular bone microstructure and is related to trabecular number, trabecular separation, and connectivity density.<sup>30</sup> Higher scores indicate stronger and fracture-resistant microarchitecture, whereas lower scores indicate deterioration in trabecular microarchitecture and higher risk for fracture. For TBS analyses, the same vertebrae were included as for LS aBMD. The TBS software is valid for use in individuals within the BMI range of 15–37 kg/m<sup>2</sup>, and thus, individuals with BMI outside this range were excluded from TBS analyses.


Before the start of the trial, each study center performed 10 repeat scans of the European Spine Phantom which were used for cross-calibration of the four different DXA machines. Each of the DXA machines was calibrated daily throughout the trial. Participant positioning and scan acquisition were conducted according to standard operating procedures. A designated quality assurance center (Berlin) and experienced DXA technician (GA) ensured consistency in scan acquisition and analysis between the different densitometry sites. Other responsibilities included instrument quality control (monitoring of short- and long-term performance of DXA machines), and training and certification of all staff involved in DO-HEALTH DXA data collection.

The coefficient of variation (CV) for measurement reliability was established at the study center in Zurich, involving 3 DXA technicians and 30 participants. CV was 0.7% for LS, 1.2% for FN, and 0.9% for TH aBMD.

## Statistical analyses and power calculations

Characteristics of study participants are described overall and by treatment group. Normally distributed continuous variables are presented as mean and standard deviation (SD) and non-normally distributed variables as median and interquartile range (IQR). Categorical variables are presented in frequencies and percentages.

The treatment effects on aBMD and TBS outcomes were analyzed based on the intent-to-treat principle. Separate mixed effects models with changes from baseline to 1, 2, and 3 years in aBMD and TBS as repeated outcomes were fit to data with robust standard errors. The mixed effects models were adjusted for the randomization stratification factors (study center, age, sex, prior fall, BMI, and the baseline level of the outcome). To determine whether the treatment effects are additive, three-way and two-way interactions were examined first. If none of the treatment interaction effects were significant ( $P < .05$ ), three dichotomous indicators were added to the model for the main treatment effects. Otherwise, an eight-level treatment group categorical variable was added to the model. For each outcome, effects of treatment, time, and treatment by time interaction were examined using one regression model. Time was entered to



**Figure 1.** Flow of participants undergoing DXA scanning in the DO-HEALTH trial. \*Reasons for exclusion are described in the DO-HEALTH primary outcome paper.<sup>27</sup>

the model as categorical variable. Adjusted means (AMs) and 95% confidence intervals are presented. The respective comparison group for additive effects of the treatments, that is when the dichotomous treatment variables are added to the model, is always the group that did not receive the respective samples. In case of synergistic treatment effects, each treatment combination is compared with placebo.

The following predefined subgroup analyses were performed: sex (female, male); age (70–74 vs.  $\geq 75$  years), baseline physical activity (below and above median of the Nurses' Health Study Physical Activity Questionnaire [NHS PAQ score]); dietary calcium intake ( $< 1000$  or  $\geq 1000$  mg), assessed by a comprehensive food frequency questionnaire; baseline serum 25(OH)D levels ( $< 20$  or  $\geq 20$  ng/mL); and fracture history in the 10 years prior to enrolment (yes/no), assessed by participant self-report. For subgroup analyses, significance of interactions between subgroup and treatment was assessed first. If the interaction was significant ( $P < .05$ ), then stratified

analyses were performed by each level of the subgroup factor. Significance level was set at 0.05 (two-sided) and analyses were performed in SAS v9.4 statistical software (Copyright© 2004 by SAS Institute Inc., Cary, NC, USA) or R Studio.

Power calculations were based on primary outcomes.<sup>19</sup> No a priori sample size calculations were conducted for BMD and TBS outcomes.

## Results

### Study participants

DXA scans were available for 1493 participants. The number of participants who underwent DXA scanning at follow up and could be included in the analyses was 1342 for FN aBMD, 1341 for TH aBMD, 1119 for LS aBMD, and 1098 for TBS. The CONSORT diagram of participant flow for this subsample of DO-HEALTH participants is shown in Figure 1. The mean age of participants was 74 years and 63% were female.

Baseline mean FN T-score was  $-1.4$ , and based on that score, 12% participants had osteoporosis, 55% had low bone mass (osteopenia), and 30% had healthy bone density at baseline. A history of low-trauma fractures in the 10 years prior to enrolment was reported by 162 (11%) participants and 7% took antiresorptive bone medications. Mean vitamin D levels at baseline were 21.9 ng/mL and 44% of participants were vitamin D deficient ( $25[\text{OH}]\text{D} < 20$  ng/mL). Median dietary calcium intake (not including supplements) was 1297 mg/d, participants had good mobility (mean SPPB score at baseline 10.7) and were physically active (Nurses' Health Study questionnaire, mean METs: 36.6; 80.4% were moderately to vigorously physically active).

Baseline characteristics were generally balanced by treatment groups, except for LS and FN T-scores in the group randomized to omega-3s compared with those randomized to control (Table 1).

Adherence data to the study interventions in this study sample of 1496 DO-HEALTH participants with DXA measurements are presented in Supplementary Table S1. By year 3,  $\geq 79\%$  still took at least 80% of their total study pills and  $\geq 65\%$  performed the home exercise program at least twice per week.

### Lumbar spine aBMD

For LS aBMD, there were no significant three- or two-way treatment interactions. Therefore, results from main effect analyses are presented and treatment effects are additive. For vitamin D, omega-3s, and SHEP, there were no significant differences between treatment and comparison groups across the 3 years of follow-up (Table 2). Also, there were no significant benefits for the combination of treatments over time (Supplementary Figure S1). However, there was a significant interaction for the subgroup by sex and vitamin D treatment ( $P = .005$ ; Supplementary Table S2). Vitamin D versus no vitamin D had a beneficial effect on LS aBMD in males ( $\Delta\text{AMs}$ : 0.0070 [95% CI, 0.0007, 0.0132] g/cm<sup>2</sup>,  $P = .029$ ) but not in females (Figure 2).

### Femoral neck aBMD

For FN aBMD, there were no three- or two-way treatment interactions. Therefore, results from main effect analyses are presented and treatment effects are additive. For vitamin D, omega-3s, and SHEP, there were no significant differences between treatment and comparison groups across the 3 years (Table 2). Similarly, there were no significant effects of treatment combinations across the 3 years (Supplementary Figure S2). Regarding subgroup analyses, there were no significant interactions between any of the subgroups and treatments for FN aBMD (Supplementary Table S2).

### Total hip aBMD

For TH aBMD, there were no three- or two-way treatment interactions. Therefore, results from main effect analyses are presented and treatment effects are additive. Vitamin D versus no vitamin D treatment had a significant positive effect on TH aBMD across the 3 years ( $\Delta\text{AMs}$ : 0.0035 [95% CI, 0.0011, 0.0059] g/cm<sup>2</sup>,  $P = .005$ ). The positive effects of vitamin D were evident at year 2 ( $\Delta\text{AMs}$ : 0.0042 [95% CI, 0.0014, 0.0070] g/cm<sup>2</sup>) and year 3 ( $\Delta\text{AMs}$ : 0.0045 [95% CI, 0.0012, 0.0078] g/cm<sup>2</sup>; Table 2). Also the combination of vitamin D + omega-3s versus no vitamin D + no omega-3s showed

a benefit across 3 years ( $\Delta\text{AMs}$ : 0.0038 [95% CI, 0.0003, 0.0072] g/cm<sup>2</sup>,  $P = .033$ ; Figure 3), however only minimally different to vitamin D alone. Regarding subgroup analyses, there were no significant interactions between any of the subgroups and treatments for TH aBMD (Supplementary Table S2).

### Lumbar spine TBS

For TBS, there was a significant three-way treatment interaction ( $P = .012$ ); consequently, effects of the seven treatment combinations were compared with placebo. Here, only omega-3s plus SHEP compared with placebo had a significant positive effect on LS TBS across the 3 years ( $\Delta\text{AMs}$ : 0.0115 [95% CI, 0.0011, 0.0219],  $P = .030$ ; Supplementary Table S3). Regarding subgroup analyses, there were no significant interactions between any of the subgroups and treatments for TBS (Supplementary Table S4).

## Discussion

In this 3-year, multi-center randomized controlled trial, including a subsample of 1493 DO-HEALTH participants with DXA measurements at baseline, 12, 24, and 36 months follow-up, supplementation with 2000 IU vitamin D3 per day had a small benefit on TH aBMD in all participants, and a small benefit on LS aBMD in men. However, there was no benefit of vitamin D on other aBMD sites. Also, the simple home exercise program and omega-3s treatment showed no effects on aBMD in generally healthy, largely vitamin D replete and active adults age 70 and older. In an exploratory analysis of TBS, there was a suggestion that the combination of SHEP and 1 g of marine omega-3s per day may improve TBS. Given the small effect sizes, the clinical impact of our findings is unclear.

The observed small benefit of vitamin D treatment on TH aBMD in DO-HEALTH (3-year change: 0.0035 g/cm<sup>2</sup>,  $\approx 0.39\%$ ) is consistent with a large meta-analysis of 41 clinical trials (0.34%, 95% CI, 0.13–0.55)<sup>31,32</sup> but was not confirmed in an ancillary study of the VITAL trial among 771 older adults (mean age 64 years).<sup>33</sup> The difference in findings between VITAL and DO-HEALTH for the same daily dose of 2000 IU vitamin D may be explained by the larger sample size in DO-HEALTH for this outcome, the older age group enrolled in DO-HEALTH (mean age 74 years in DO-HEALTH vs. 64 years in VITAL) and possibly by the lower baseline  $25(\text{OH})\text{D}$  levels in DO-HEALTH participants (21.9 ng/mL in DO-HEALTH vs. 27.7 ng/mL). Additionally, we found a beneficial effect of vitamin D on spine aBMD, although it was limited to men. This sex-specific benefit on spine aBMD remains unclear, but may possibly be attributed a greater proportion of males with vitamin D deficiency at baseline (male: 48.7% vs. female: 40.9%) and a somewhat lower baseline calcium intake in males (1253 vs. 1326 mg/d). Consideration of multiple comparisons is warranted when interpreting these findings. Furthermore, effects on both, TH and LS aBMD, are considerably smaller than the suggested aBMD difference required to show a fracture risk reduction (1.4% for vertebral and 3.2% for hip fractures),<sup>34</sup> and thus, clinical impact of our findings may be limited.

To the best of our knowledge, this is the largest RCT reporting the effect of supplemental omega-3s on aBMD in older adults. Our findings align with a meta-analysis that compared higher (aim for  $\geq 10\%$  increase in total intake, from

Table 1. Baseline characteristics of study participants.


Characteristics	Vitamin D			Omega-3 s			Exercise			
	Overall (n = 1493)	Vitamin D (n = 745)	No vitamin D (n = 748)	P	Omega-3 s (n = 749)	No omega-3 s (n = 744)	P	SHEP (n = 749)	Control exercise (n = 744)	P
Age [yrs], median [IQR] <sup>a</sup>	74.0 [71.0, 77.0]	74.0 [71.0, 78.0]	74.0 [72.0, 77.0]	0.786	74.00 [71.00, 77.00]	74.00 [72.00, 77.25]	0.493	74.00 [71.00, 77.00]	74.00 [71.75, 77.00]	0.756
BMI [kg/m <sup>2</sup> ], mean (SD) <sup>b</sup>	26.63 (4.31)	26.75 (4.42)	26.50 (4.19)	0.270	26.61 (4.25)	26.64 (4.37)	0.919	26.64 (4.29)	26.61 (4.34)	0.887
Female, n (%)	945 (63.3)	477 (64.0)	468 (62.6)	0.595	476 (63.6)	469 (63.0)	0.879	473 (63.2)	472 (63.4)	0.950
Comorbidity score, median [IQR] <sup>b, c</sup>	3.0 [1.0, 5.0]	3.0 [1.0, 5.0]	3.0 [1.0, 5.0]	0.983	3.00 [1.00, 5.00]	3.00 [1.00, 5.00]	0.992	2.00 [1.00, 5.00]	3.00 [1.00, 5.00]	0.253
LS T-score, mean (SD)	-1.27 (1.43)	-1.29 (1.37)	-1.26 (1.48)	0.806	-1.41 (1.35)	-1.14 (1.50)	0.001	-1.25 (1.38)	-1.30 (1.48)	0.562
FN T-score, mean (SD)	-1.43 (1.00)	-1.44 (0.96)	-1.43 (1.03)	0.812	-1.49 (0.97)	-1.37 (1.03)	0.018	-1.42 (0.99)	-1.44 (1.01)	0.747
Bone status based on FN T-score <sup>d</sup>				0.067			0.261			0.357
Healthy, n (%)	451 (30.3)	213 (28.7)	238 (32.0)		219 (29.4)	232 (31.3)		224 (30.0)	227 (30.7)	
Osteopenia, n (%)	814 (54.8)	427 (57.5)	387 (52.0)		403 (54.2)	411 (55.4)		423 (56.6)	391 (52.9)	
Osteoporosis, n (%)	181 (12.2)	79 (10.6)	102 (13.7)		103 (13.8)	78 (10.5)		82 (11.2)	99 (13.8)	
Bone medication intake, n (%)	109 (7.3)	56 (7.5)	53 (7.1)	0.825	57 (7.6)	52 (7.0)	0.718	54 (7.2)	55 (7.4)	0.971
Fracture history, n (%)	162 (10.9)	87 (11.7)	75 (10.0)	0.325	73 (9.7)	89 (12.0)	0.106	75 (10.0)	87 (11.7)	0.484
SPPB score, mean (SD) <sup>e</sup>	10.72 (1.55)	10.76 (1.53)	10.68 (1.56)	0.335	10.66 (1.62)	10.77 (1.47)	0.197	10.71 (1.55)	10.72 (1.55)	0.846
Daily calcium intake [mg], median [IQR] <sup>a, f</sup>	1297 [1006, 1724]	1284 [1010, 1694]	1301 [1005, 1771]	0.423	1292 [1017, 1730]	1302 [1005, 1720]	0.921	1322 [1031, 1724]	1285 [981, 1725]	0.278
Physical activity level, n(%)				0.05			0.927			0.927
Inactive	293 (19.6)	128 (17.1)	165 (22.1)		149 (20.0)	144 (19.3)		149 (20.0)	144 (19.3)	
Moderately active (1–3 times/week)	474 (31.8)	247 (33.1)	227 (30.5)		236 (31.7)	238 (31.8)		236 (31.7)	238 (31.8)	
Active (>3 times/week)	725 (48.6)	372 (49.8)	353 (47.4)		359 (48.3)	366 (48.9)		359 (48.3)	366 (48.9)	
Serum 25-hydroxyvitamin D concentration [ng/mL], mean (SD)	21.85 (8.36)	21.95 (8.44)	21.75 (8.28)	0.633	21.76 (8.37)	21.94 (8.36)	0.682	22.33 (8.50)	21.37 (8.19)	0.028
Vitamin D deficiency (<20 ng/mL), n (%)	648 (43.8)	311 (42.1)	337 (45.4)	0.232	323 (43.5)	325 (44.0)	0.904	312 (42.1)	336 (45.4)	0.220

Abbreviations: BMI, body mass index; FN, femoral neck; IQR, interquartile range; LS, lumbar spine; SHEP, strength-training home exercise program; SPPB, short physical performance battery; yrs, years. <sup>a</sup>Median and IQR are presented for non-normally distributed variables. <sup>b</sup>BMI was calculated as weight in kilograms divided by height in meters squared. <sup>c</sup>Comorbidity was measured by the Self-Administered Comorbidity Questionnaire, which assesses 12 comorbidities by 3 dimensions (presence, medication, and limitation of activities). It has a range of 0–36 points and lower scores indicate better health. <sup>d</sup>A T-score of >1.0 was defined as healthy, ≤-1.0 to >-2.5 as osteopenia and ≤-2.5 as osteoporosis. <sup>e</sup>The SPPB assesses lower extremity function. Scores range from 0 to 12, in which higher scores are better. <sup>f</sup>Assessed by an electronic food frequency questionnaire, specifically developed for DO-HEALTH and targeted to older adults.


**Table 2.** Change from baseline in aBMD outcomes [g/cm<sup>2</sup>].

	Vitamin D	No vitamin D	Difference (95% CI)	P-value	Omega-3 s	No Omega-3 s	Difference (95% CI)	P-value	SHEP	Control exercise	Differences (95% CI)	P-value
<b>LS aBMD</b>												
Unadjusted at baseline, n= 1214	1.0398	1.0440	-0.0043	0.692	1.0262	1.0577	-0.0315	0.003	1.0414	1.0367	0.0085	0.428
Adjusted change from baseline	(1.0268, 1.0567)	(1.0292, 1.0589)	(-0.0253, 0.0168)		(1.0113, 1.0411)	(1.0428, 1.0725)	(-0.0525, -0.0104)		(1.0264, 1.0565)	(1.0217, 1.0517)	(-0.0125, 0.0296)	
Year 1	0.0027	0.0020	0.0008		0.0021	0.0025	-0.0004		0.0004	0.0043	-0.0040	
	(-0.0, 0.0054)	(-0.0007, 0.0046)	(-0.0030, 0.0045)		(0.0006, 0.0048)	(-0.0002, 0.0052)	(-0.0042, 0.0034)		(-0.0024, 0.0031)	(0.0016, 0.0070)	(-0.0077, -0.0002)	
Year 2	0.0028	0.0032	-0.0004		0.0023	0.0036	-0.0013		0.0033	0.0043	0.0007	
	(-0.0004, 0.0059)	(0.0, 0.0063)	(-0.0048, 0.0040)		(-0.0009, 0.0055)	(0.0005, 0.0068)	(-0.0058, 0.0031)		(0.0002, 0.0065)	(-0.0005, 0.0057)	(-0.0037, 0.0051)	
Year 3	0.0044	0.0032	0.0011		0.0032	0.0044	-0.0011		0.0034	0.0042	-0.0008	
	(0.0008, 0.0080)	(-0.0003, 0.0068)	(0.0039, 0.0062)		(-0.0004, 0.0068)	(0.0008, 0.0079)	(-0.0062, 0.0039)		(-0.0002, 0.0070)	(0.0007, 0.0078)	(-0.0059, 0.0042)	
Average across 3 years	0.0033	0.0028	0.0005	0.789	0.0026	0.0035	-0.0010	0.614	0.0024	0.0037	-0.0014	0.477
	(0.0006, 0.0060)	(0.0001, 0.0054)	(-0.0032, 0.0042)		(-0.0001, 0.0052)	(0.0008, 0.0062)	(-0.0047, 0.0028)		(-0.0003, 0.0050)	(0.0011, 0.0064)	(-0.0051, 0.0024)	
<b>FN aBMD</b>												
Unadjusted at baseline, n= 1452	0.8343	0.8375	-0.0032	0.639	0.8280	0.8438	-0.0158	0.022	0.8373	0.8345	0.0028	0.681
Adjusted change from baseline	(0.8247, 0.8439)	(0.8280, 0.8471)	(-0.0168, 0.01030)		(0.8184, 0.8376)	(0.8342, 0.8534)	(-0.0294, -0.0023)		(0.8278, 0.8469)	(0.8249, 0.8441)	(-0.0107, 0.0164)	
Year 1	0.0071	0.0077	-0.0006		0.0053	0.0095	-0.0043		0.0069	0.0080	-0.0011	
	(0.0040, 0.102)	(0.0047, 0.108)	(-0.0049, 0.0036)		(0.0022, 0.0093)	(0.0065, 0.0126)	(-0.0085, 0)		(0.0038, 0.0099)	(0.0049, 0.0110)	(-0.0054, 0.0032)	
Year 2	0.0030	0.0037	-0.0007		0.0012	0.0054	-0.0042		0.0023	0.0043	-0.0020	
	(-0.0003, 0.0062)	(0.0005, 0.0069)	(-0.0052, 0.0037)		(-0.0020, 0.0044)	(0.0022, 0.0086)	(-0.0087, 0.0003)		(-0.0009, 0.0056)	(0.0011, 0.0075)	(-0.0064, 0.0025)	
Year 3	-0.0017	-0.0047	0.0030		-0.0046	-0.0018	-0.0027		-0.0040	-0.0024	-0.0016	
	(-0.0054, 0.0020)	(-0.0083, -0.0010)	(-0.0022, 0.0081)		(-0.0082, -0.0009)	(-0.0055, 0.0018)	(-0.0079, 0.0024)		(-0.0077, -0.0003)	(-0.0061, 0.0013)	(-0.0067, 0.0035)	
Average across 3 years	0.0028	0.0022	0.0005	0.800	0.0006	0.0044	-0.0037	0.076	0.0017	0.0033	-0.0016	0.461
	(-0.0002, 0.0058)	(-0.0007, 0.0052)	(-0.0036, 0.0047)		(-0.0023, 0.0036)	(0.0014, 0.0073)	(-0.0079, 0.0004)		(-0.0012, 0.0047)	(0.0003, 0.0062)	(-0.0057, 0.0026)	
<b>TH aBMD</b>												
Unadjusted at baseline, n= 1451	0.8981	0.8983	-0.0002	0.979	0.8899	0.9066	-0.0167	0.029	0.9000	0.8967	0.0033	0.663
Adjusted change from baseline	(0.8875, 0.9088)	(0.8877, 0.9089)	(-0.0152, 0.0148)		(0.8793, 0.9005)	(0.8960, 0.9172)	(-0.0317, -0.0017)		(0.8893, 0.9105)	(0.8859, 0.9072)	(-0.0117, 0.0184)	
Year 1	0.0022	0.0003	0.0019		0.0013	0.0012	0.0001		0.0005	0.0020	-0.0016	
	(0.0005, 0.0039)	(-0.0014, 0.0020)	(-0.0005, 0.0043)		(-0.0004, 0.0030)	(-0.0006, 0.0029)	(-0.0023, 0.0025)		(-0.0013, 0.0022)	(0.0003, 0.0037)	(-0.0040, 0.0008)	
Year 2	-0.0009	-0.0051	0.0042		-0.0031	-0.0028	-0.0003		-0.0039	-0.0020	-0.0019	
	(-0.0029, 0.0011)	(-0.0071, -0.0031)	(0.0014, 0.0070)		(-0.0051, -0.0011)	(-0.0048, -0.0008)	(-0.0031, 0.0025)		(-0.0059, -0.0019)	(-0.0040, -0.0000)	(-0.0047, 0.0009)	
Year 3	-0.0053	-0.0098	0.0045		-0.0071	-0.0080	0.0009		-0.0085	-0.0066	-0.0019	
	(-0.0077, -0.0030)	(-0.0121, -0.0075)	(0.0012, 0.0078)		(-0.0095, -0.0048)	(-0.0104, -0.0057)	(-0.0024, 0.0042)		(-0.0109, -0.0062)	(-0.0090, -0.0043)	(-0.0052, 0.0014)	
Average across 3 years	-0.0013	-0.0049	0.0035	0.005	-0.0030	-0.0032	0.0002	0.840	-0.0040	-0.0022	-0.0018	0.147
	(-0.0031, 0.0004)	(-0.0066, -0.0031)	(0.0011, 0.0059)		(-0.0047, -0.0012)	(-0.0050, -0.0015)	(-0.0022, 0.0027)		(-0.0057, -0.0023)	(-0.0039, -0.0005)	(-0.0042, 0.0006)	

Abbreviations: aBMD, areal bone mineral density; SHEP, strength-training home exercise program. Analyses were adjusted for age, sex, BMI, prior fall, study site, and baseline level of the outcome.



**Figure 2.** 3-year average change in LS aBMD for vitamin D versus no vitamin D overall and by sex. Abbreviations: aBMD, areal bone mineral density; CI, confidence interval; yr, year. Analyses were adjusted for age, sex, BMI, prior fall, study site, and baseline LS aBMD, *N* = 1119.



**Figure 3.** 3-year average change in TH aBMD for treatment combinations compared with the respective group not receiving the treatment. Abbreviations: aBMD, areal bone mineral density; CI, confidence interval; SHEP, strength-training home exercise program; yr, year. Analyses were adjusted for age, sex, BMI, prior fall, study site, and baseline TH aBMD. *N* = 1341.

diet or supplements) versus lower omega-3s intake and concluded no benefit at any of the measuring sites.<sup>22</sup> In contrast, a recent meta-analysis of RCTs among middle-aged adults ( $\geq 50$  years) reported a small benefit of any type of omega-3s supplementation (0.005 g/cm<sup>2</sup>, 95% CI, 0.000–0.010; 7 interventions), most pronounced for EPA and DHA combined (0.026 g/cm<sup>2</sup>, 95% CI, 0.022–0.030).<sup>23</sup> However, that meta-analysis is restricted by the small number of included trials, small sample sizes per trial (<100 participants/group), and lack of specification of which bone site (eg, LS, FN) was used. Based on our findings and existing evidence, there is no high-quality evidence to support omega-3s supplementation to improve bone health in generally healthy older adults today.

The beneficial effects of exercise on aBMD and bone microarchitecture have been well established.<sup>26,35</sup> There are two main reasons that may explain the lack of benefit of the DO-HEALTH exercise program on aBMD. First, the SHEP program was of relatively low intensity and included minimal external resistance (ie, light elastic band) which also was not progressed in intensity across the 3 years. Second, 80% of DO-HEALTH participants were already engaging in moderate to vigorous physical activity at baseline.<sup>27</sup> As suggested by the literature, in order to have an osteogenic effect, an exercise intervention needs to exceed habitual bone loading.<sup>36</sup> Therefore, our exercise program in the generally healthy and active DO-HEALTH population may have been insufficient to stimulate an effect on aBMD.<sup>36</sup> It is important to note that our findings do neither invalidate the benefits of exercise for

bone health and healthy aging, nor do they invalidate previous beneficial effects of SHEP for fall and fracture prevention in frail older adults with acute hip fracture.<sup>37</sup>

As an exploratory outcome, we also assessed TBS, which is still a relatively novel analytical tool in the evaluation of trabecular microstructure, osteoporosis, and fracture risk.<sup>30,38</sup> Few trials to date have used TBS to evaluate effects of vitamin D,<sup>38–41</sup> omega-3 s,<sup>43</sup> or exercise,<sup>44</sup> and the majority of those trials are limited by small sample sizes (eg,  $\leq 200$  participants)<sup>39,40,41–43</sup> and short follow-up durations<sup>45</sup> ( $\leq 6$  months).<sup>39,40,44</sup> DO-HEALTH was the first trial to examine individual and combined effects of vitamin D, omega-3s, and exercise on TBS and suggests a synergistic effect of combined omega-3s supplementation and SHEP across the 3-year follow-up. Of note, this effect only became significant at 3 years.

This study has several limitations. First, study participants were not selected for vitamin D deficiency, low bone mass, or increased fracture risk at baseline, which may have limited the ability to detect a significant treatment effect. Second, there were some imbalances in baseline LS and FN T-score for the omega-3 s versus no omega-3s groups. This limitation was addressed by adjusting all analyses for baseline level of the outcome measure. Third, the observed effects of 0.0035 g/cm<sup>2</sup> ( $\approx 0.4\%$ ) at the TH and 0.0070 g/cm<sup>2</sup> ( $\approx 0.7\%$ ) at the LS across the 3 years are relatively small and did not exceed LSC measured at the study center in Zurich (TH: 0.022 g/cm<sup>2</sup>, spine: 0.021 g/cm<sup>2</sup>).<sup>46</sup> Fourth, we did not adjust the *P* values



for multiple testing. Given the large number of comparisons, the significance threshold of  $P = .05$  may have been too liberal, and statistically significant results may have occurred by chance. Finally, restriction of recruitment to generally healthy older adults, unselected for low bone mass or osteoporosis at baseline, limits generalizability of our findings to populations at risk for osteoporosis and fractures but also defines a conservative approach for the three interventions tested.

In conclusion, we observed a benefit of 2000 IU of supplemental vitamin D3 per day on total hip aBMD overall and on lumbar spine aBMD in males; however, effects were small and clinical significance of the findings thus unclear. Omega-3s supplementation and a simple strength training home exercise program appear to have no benefits for aBMD in generally healthy older adults.

## Acknowledgments

The members of DO-HEALTH Research Group are listed here: Bischoff-Ferrari Heike A., Egli Andreas, Rival Sandrine, Wanner Guido A., Vellas Bruno, Guyonnet Sophie, Rizzoli René, Biver Emmanuel, Merminod Fanny, Kressig Reto W., Bridenbaugh Stephanie, Suhm Norbert, Da Silva José A.P., Duarte Cátia C.M., Pinto Filipa Ana, Felsenberg Dieter, Börst Hendrikje, G.A., Blauth Michael, Spicher Anna, Felson David T., Eugene V. McCloskey, Johansson Elena, Watzl Bernhard, Gomez Rodriguez Manuel, Hofbauer Lorenz, Tsourdi Elena, Rauner Martina, Siebert Uwe, Kanis John A., Halbout Philippe, M. Ferrari Stephen, Gut Benno, Ba Marième, Wittwer Schegg Jonas, Etheve Stéphane, Eggersdorfer Manfred, Delannoy Carla Sofa, Reuschling Monika, Orav Endel J., Willett Walter C., JoAnn E. Manson, Dawson-Hughes Bess, Staehelin Hannes B., Walter Paul W., Dick Walter, Fried Michael, Ivon Eckardstein Arnold, Theiler Robert, Simmen Hans-Peter, Langhans Wolfgang, Zinkernagel Annelies, Mueller Nicolas, Distler Oliver, Graetz Klaus, Nitschke Ina, Dietrich Thomas, Baer Walter, Landau Klara, Ruschitzka Frank, Manz Markus, Burckhardt Peter.

## Author contributions

Melanie Kistler-Fischbacher (Data curation, Formal analysis, Funding acquisition, Investigation, Project administration, Validation, Visualization, Writing—original draft, Writing—review & editing), Gabriele Armbrrecht (Data curation, Investigation, Methodology, Project administration, Resources, Validation, Writing—review & editing), Stephanie Gängler (Formal analysis, Software, Validation, Visualization, Writing—original draft, Writing—review & editing), Robert Theiler (Supervision, Writing—review & editing), René Rizzoli (Conceptualization, Investigation, Methodology, Project administration, Resources, Supervision, Writing—review & editing), Bess Dawson-Hughes (Methodology, Supervision, Writing—review & editing), John Kanis (Methodology, Supervision, Writing—review & editing), Lorenz Hofbauer (Supervision, Writing—review & editing), Ralph Schimmer (Supervision, Writing—review & editing), Bruno Vellas (Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing—review & editing), José Da Silva (Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing—review & editing), Endel Orav (Formal analysis, Methodology, Writing—review & editing), Reto Kressig (Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing—review & editing), Andreas Egli (Conceptualization, Investigation, Methodology, Project administration, Writing—review & editing), Wei Lang (Formal analysis, Software, Writing—review & editing), Guido Wanner (Formal analysis, Supervision, Writing—original draft, Writing—review & editing), and Heike Bischoff-Ferrari (Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing—original draft, Writing—review & editing)

## Supplementary material

Supplementary material is available at *Journal of Bone and Mineral Research* online.

## Funding

DO-HEALTH was funded under the 7th framework program of the European Union (EC-GA No. 278588), and within this framework, also by the University of Zurich (Chair for Geriatric Medicine and Aging Research), DSM nutritional products AG, ROCHE Diagnostics (Switzerland) AG, NESTEC S.A., Pfizer Consumer Healthcare GmbH, and STREULI Pharma AG. This analysis was funded by an independent personal grant (MK-F) by Vontobel Foundation. The funding/supporting organizations had no role in the design and conduct of DO-HEALTH, including collection, management, analysis, and interpretation of the data, as well as preparation, review, or approval of the manuscript or decision to submit the manuscript for publication.

## Conflicts of interest

G.A. declares institutional grants from Bayer AG, Madrigal Pharmaceuticals, and Deutsches Zentrum für Luft- und Raumfahrt (DLR), consulting fees from Porous GmbH and honoraria from Landesanstalt für Personendosimetrie und Strahlenschutz Ausbildung. J.A.K. is a board member of IOF, ESCO, and NOGG, and a director of Osteoporosis Research Ltd. (UK) and Patron of Osteoporosis 2000 (UK). L.C.H. declares consulting fees from Amgen, Ascendis, UCB, Pharmacosmos and honoraria from NovoNordisk. R.C.S. declares an employee contract and stock with Roche, honoraria for lectures and testimony by the Hirslanden hospital group, and Innosuisse, respectively, and participation in an advisory board with Hygiaso. J.A.P.D. has received speaker fees from AMGEN and was the scientific director of FORUM D, an industry-sponsored online platform in Portuguese dedicated to the dissemination of evidence regarding Vitamin D effects on health. H.A.B.-F. reports as the PI of the DO-HEALTH trial, grants from the European Commission (Grant Agreement No. 278588), from the University of Zurich, from NESTEC, from PFIZER Consumer Healthcare, from Streuli Pharma, plus non-financial support from DSM Nutritional Products and from Roche Diagnostics. Furthermore, H.A.B.-F. reports speaker fees from Wild, Pfizer, Vifor, Mylan, Roche Diagnostics, and independent and investigator initiated grants from Pfizer and from Vifor, outside the submitted work. M.K.-F., S.G., R.T., R.R., B.D.-H., B.V., E.J.O., R.W.K., A.E., W.L., G.A.W. declare no conflict of interest.

## Data availability

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

## References

- Osteoporosis prevention, diagnosis, and therapy. *JAMA*. 2001;285(6):785–795. <https://doi.org/10.1001/jama.285.6.785>
- Kanis JA, Norton N, Harvey NC, et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. *Arch Osteoporos*. 2021;16(1):82. <https://doi.org/10.1007/s11657-020-00871-9>
- Haentjens P, Magaziner J, Colón-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. *Ann Intern Med*. 2010;152(6):380–390. <https://doi.org/10.7326/0003-4819-152-6-201003160-00008>
- Koelé MC, Lems WF, Willems HC. The clinical relevance of hyperkyphosis: a narrative review. *Front Endocrinol (Lausanne)*. 2020;11:5. Epub 20200124. <https://doi.org/10.3389/fendo.2020.00005>
- Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. *Lancet*. 2002;359(9319):1761–1767. [https://doi.org/10.1016/S0140-6736\(02\)08657-9](https://doi.org/10.1016/S0140-6736(02)08657-9)
- Berger C, Langsetmo L, Joseph L, et al. Association between change in BMD and fragility fracture in women and men. *J Bone*

- Miner Res.* 2009;24(2):361–370. <https://doi.org/10.1359/jbmr.081004>
7. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO study group. *World Health Organ Tech Rep Ser.* 1994;843:1–129.
  8. Hillier TA, Stone KL, Bauer DC, et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. *Arch Intern Med.* 2007;167(2):155–160. <https://doi.org/10.1001/archinte.167.2.155>
  9. Ammann P, Rizzoli R. Bone strength and its determinants. *Osteoporos Int.* 2003;14(Suppl 3):13–18. Epub 20030319. <https://doi.org/10.1007/s00198-002-1345-4>
  10. Nakamichi Y, Udagawa N, Horibe K, et al. VDR in osteoblast-lineage cells primarily mediates vitamin D treatment-induced increase in bone mass by suppressing bone resorption. *J Bone Miner Res.* 2017;32(6):1297–1308. Epub 20170222. <https://doi.org/10.1002/jbmr.3096>
  11. Christakos S, Dhawan P, Porta A, Mady LJ, Seth T. Vitamin D and intestinal calcium absorption. *Mol Cell Endocrinol.* 2011;347(1-2):25–29. Epub 20110601. <https://doi.org/10.1016/j.mce.2011.05.038>
  12. Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. *N Engl J Med.* 2012;367(1):40–49. <https://doi.org/10.1056/NEJMoa1109617>
  13. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. *BMJ.* 2009;339(oct01 1):b3692. Epub 20091001. <https://doi.org/10.1136/bmj.b3692>
  14. LeBoff MS, Bischoff-Ferrari HA. The effects of vitamin D supplementation on musculoskeletal health: the VITAL and DO-health trials. *J Gerontol A Biol Sci Med Sci.* 2023;78(Supplement\_1):73–78. <https://doi.org/10.1093/gerona/glad073>
  15. Bischoff-Ferrari HA. Hype about vitamin D substitution: what remains? *Internist (Berl).* 2020;61(11):1196–1203. <https://doi.org/10.1007/s00108-020-00869-y>
  16. Mazess RB, Bischoff-Ferrari HA, Dawson-Hughes B. Vitamin D: bolus is bogus—a narrative review. *JBMR Plus.* 2021;5(12):e10567. <https://doi.org/10.1002/jbm4.10567>
  17. Yao P, Bennett D, Mafham M, et al. Vitamin D and calcium for the prevention of fracture: a systematic review and meta-analysis. *JAMA Netw Open.* 2019;2(12):e1917789.
  18. Chakhtoura M, Bacha DS, Gharios C, et al. Vitamin D supplementation and fractures in adults: a systematic umbrella review of meta-analyses of controlled trials. *J Clin Endocrinol Metab.* 2022;107(3):882–898. <https://doi.org/10.1210/clinem/dga b742>
  19. Bischoff-Ferrari HA, de Godoi Rezende Costa Molino C, Rival S, et al. DO-HEALTH: vitamin D3 - Omega-3 - home exercise - healthy aging and longevity trial - design of a multinational clinical trial on healthy aging among European seniors. *Contemp Clin Trials.* 2021;100:106124. <https://doi.org/10.1016/j.cct.2020.106124>
  20. Orchard TS, Pan X, Cheek F, Ing SW, Jackson RD. A systematic review of omega-3 fatty acids and osteoporosis. *Br J Nutr.* 2012;107(S2):S253–S260. <https://doi.org/10.1017/S0007114512001638>
  21. Farina EK, Kiel DP, Roubenoff R, Schaefer EJ, Cupples LA, Tucker KL. Protective effects of fish intake and interactive effects of long-chain polyunsaturated fatty acid intakes on hip bone mineral density in older adults: the Framingham osteoporosis study. *Am J Clin Nutr.* 2011;93(5):1142–1151. <https://doi.org/10.3945/ajcn.110.005926>
  22. Abdelhamid A, Hooper L, Sivakaran R, Hayhoe RPG, Welch A. The relationship between Omega-3, Omega-6 and Total polyunsaturated fat and musculoskeletal health and functional status in adults: a systematic review and meta-analysis of RCTs. *Calcif Tissue Int.* 2019;105(4):353–372. Epub 20190725. <https://doi.org/10.1007/s00223-019-00584-3>
  23. Dou Y, Wang Y, Chen Z, Yu X, Ma D. Effect of n-3 polyunsaturated fatty acid on bone health: a systematic review and meta-analysis of randomized controlled trials. *Food Sci Nutr.* 2022;10(1):145–154. Epub 20211129. <https://doi.org/10.1002/fsn3.2655>
  24. Chang X, Xu S, Zhang H. Regulation of bone health through physical exercise: mechanisms and types. *Front Endocrinol (Lausanne).* 2022;13:1029475. Epub 20221207. <https://doi.org/10.3389/fendo.2022.1029475>
  25. Mages M, Shojaa M, Kohl M, et al. Exercise effects on bone mineral density in men. *Nutrients.* 2021;13(12):4244. Epub 20211126.
  26. Kistler-Fischbacher M, Weeks BK, Beck BR. The effect of exercise intensity on bone in postmenopausal women (part 2): a meta-analysis. *Bone.* 2021;143:115697. Epub 20201224. <https://doi.org/10.1016/j.bone.2020.115697>
  27. Bischoff-Ferrari HA, Vellas B, Rizzoli R, et al. Effect of vitamin D supplementation, Omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. *JAMA.* 2020;324(18):1855–1868. <https://doi.org/10.1001/jama.2020.16909>
  28. LeBoff MS, Chou SH, Ratliff KA, et al. Supplemental vitamin D and incident fractures in midlife and older adults. *N Engl J Med.* 2022;387(4):299–309. <https://doi.org/10.1056/NEJMoa2202106>
  29. LeBoff MS, Sharon HC, Kristin AR, et al. Effects of Omega-3 fatty acid supplementation on incident fractures in midlife and older adults enrolled in VITamin D and Omega-3 Trial (VITAL). *J Bone Miner Res.* 2022;38, Suppl 1). Available at. <https://www.asbmr.org/meetings/2022-abstracts> Accessed July 5, 2023.
  30. Harvey NC, Glüer CC, Binkley N, et al. Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. *Bone.* 2015;78:216–224. Epub 20150516. <https://doi.org/10.1016/j.bone.2015.05.016>
  31. Bischoff-Ferrari HA, Orav EJ, Abderhalden L, Dawson-Hughes B, Willett WC. Vitamin D supplementation and musculoskeletal health. *Lancet Diabetes Endocrinol.* 2019;7(2):85. [https://doi.org/10.1016/S2213-8587\(18\)30347-4](https://doi.org/10.1016/S2213-8587(18)30347-4)
  32. Bolland MJ, Grey A, Avenell A. Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis. *Lancet Diabetes Endocrinol.* 2018;6(11):847–858. Epub 20181004. [https://doi.org/10.1016/S2213-8587\(18\)30265-1](https://doi.org/10.1016/S2213-8587(18)30265-1)
  33. LeBoff MS, Chou SH, Murata EM, et al. Effects of supplemental vitamin D on bone health outcomes in women and men in the VITamin D and Omega-3 Trial (VITAL). *J Bone Miner Res.* 2020;35(5):883–893. Epub 20200130. <https://doi.org/10.1002/jbmr.3958>
  34. Black DM, Bauer DC, Vittinghoff E, Lui L, Grauer A, Marin F, et al. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. *Lancet Diabetes Endocrinol.* 2020;8(8):672–682. [https://doi.org/10.1016/S2213-8587\(20\)30159-5](https://doi.org/10.1016/S2213-8587(20)30159-5)
  35. Kistler-Fischbacher M, Weeks BK, Beck BR. The effect of exercise intensity on bone in postmenopausal women (part 1): a systematic review. *Bone.* 2021;143:115696. Epub 20201224. <https://doi.org/10.1016/j.bone.2020.115696>
  36. Beck BR. Exercise prescription for osteoporosis: back to basics. *Exerc Sport Sci Rev.* 2022;50(2):57–64. <https://doi.org/10.1249/JES.0000000000000281>
  37. Bischoff-Ferrari HA, Dawson-Hughes B, Platz A, et al. Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trial. *Arch Intern Med.* 2010;170(9):813–820. <https://doi.org/10.1001/archinternmed.2010.67>
  38. Krohn K, Schwartz EN, Chung YS, Lewiecki EM. Dual-energy X-ray absorptiometry monitoring with trabecular bone score: 2019 ISCD official position. *J Clin Densitom.* 2019;22(4):501–505. Epub 20190709. <https://doi.org/10.1016/j.jocd.2019.07.006>

39. Lerchbaum E, Trummer C, Theiler-Schwetz V, et al. Effects of vitamin D supplementation on bone turnover and bone mineral density in healthy men: a post-hoc analysis of a randomized controlled trial. *Nutrients*. 2019;11(4):731. <https://doi.org/10.3390/nu11040731>
40. Bislev LS, Langagergaard Rødbro L, Rolighed L, Sikjaer T, Rejnmark L. Bone microstructure in response to vitamin D3 supplementation: a randomized placebo-controlled trial. *Calcif Tissue Int*. 2019;104(2):160–170. Epub 20181006. <https://doi.org/10.1007/s00223-018-0481-6>
41. Hansen KE, Johnson RE, Chambers KR, et al. Treatment of vitamin D insufficiency in postmenopausal women: a randomized clinical trial. *JAMA Intern Med*. 2015;175(10):1612–1621. <https://doi.org/10.1001/jamainternmed.2015.3874>
42. Di Gregorio S, Del Rio L, Rodriguez-Tolra J, Bonel E, García M, Winzenrieth R. Comparison between different bone treatments on areal bone mineral density (aBMD) and bone microarchitectural texture as assessed by the trabecular bone score (TBS). *Bone*. 2015;75:138–143. Epub 20150106. <https://doi.org/10.1016/j.bone.2014.12.062>
43. Jørgensen HS, Eide IA, Jenssen T, et al. Marine n-3 polyunsaturated fatty acids and bone mineral density in kidney transplant recipients: a randomized, placebo-controlled trial. *Nutrients*. 2021;13(7):2361. Epub 20210710.
44. Pinho JP, Forner-Cordero A, Rodrigues Pereira RM, et al. A high-intensity exercise intervention improves older women lumbar spine and distal tibia bone microstructure and function: a 20-week randomized controlled trial. *IEEE J Transl Eng Health Med*. 2020;8:2100108. Epub 20200103–8. <https://doi.org/10.1109/JTEHM.2019.2963189>
45. Clarke B. Normal bone anatomy and physiology. *Clin J Am Soc Nephrol*. 2008;3(Suppl 3):S131–S139.
46. Shepherd JA. Positions of the international society for clinical densitometry and their etiology: a scoping review. *J Clin Densitom*. 2023;26(3):101369. <https://doi.org/10.1016/j.jocd.2023.101369>